217 related articles for article (PubMed ID: 23817689)
1. Genomic heterogeneity of translocation renal cell carcinoma.
Malouf GG; Monzon FA; Couturier J; Molinié V; Escudier B; Camparo P; Su X; Yao H; Tamboli P; Lopez-Terrada D; Picken M; Garcia M; Multani AS; Pathak S; Wood CG; Tannir NM
Clin Cancer Res; 2013 Sep; 19(17):4673-84. PubMed ID: 23817689
[TBL] [Abstract][Full Text] [Related]
2. Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.
Hayes M; Peckova K; Martinek P; Hora M; Kalusova K; Straka L; Daum O; Kokoskova B; Rotterova P; Pivovarčikova K; Branzovsky J; Dubova M; Vesela P; Michal M; Hes O
Virchows Arch; 2015 Mar; 466(3):313-22. PubMed ID: 25544614
[TBL] [Abstract][Full Text] [Related]
3. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
J Hematol Oncol; 2021 Mar; 14(1):46. PubMed ID: 33741027
[TBL] [Abstract][Full Text] [Related]
4. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes.
Malouf GG; Su X; Yao H; Gao J; Xiong L; He Q; Compérat E; Couturier J; Molinié V; Escudier B; Camparo P; Doss DJ; Thompson EJ; Khayat D; Wood CG; Yu W; Teh BT; Weinstein J; Tannir NM
Clin Cancer Res; 2014 Aug; 20(15):4129-40. PubMed ID: 24899691
[TBL] [Abstract][Full Text] [Related]
6. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
Yin X; Wang B; Gan W; Zhuang W; Xiang Z; Han X; Li D
J Exp Clin Cancer Res; 2019 Mar; 38(1):119. PubMed ID: 30849994
[TBL] [Abstract][Full Text] [Related]
7. Racial Disparities in MiT Family Translocation Renal Cell Carcinoma.
Lu X; Tawanaie Pour Sedehi N; Su X; Yan F; Alhalabi O; Tannir NM; Malouf GG
Oncologist; 2023 Nov; 28(11):1009-1013. PubMed ID: 37315151
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
[TBL] [Abstract][Full Text] [Related]
10. Chameleon TFE3-translocation RCC and How Gene Partners Can Change Morphology: Accurate Diagnosis Using Contemporary Modalities.
Tretiakova MS
Adv Anat Pathol; 2022 May; 29(3):131-140. PubMed ID: 35180736
[TBL] [Abstract][Full Text] [Related]
11. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
12. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.
Classe M; Malouf GG; Su X; Yao H; Thompson EJ; Doss DJ; Grégoire V; Lenobin J; Fantoni JC; Sudour-Bonnange H; Khayat D; Aubert S; Tannir NM; Leroy X
Histopathology; 2017 Jun; 70(7):1089-1097. PubMed ID: 28106924
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
[TBL] [Abstract][Full Text] [Related]
14. Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma.
Sun G; Chen J; Liang J; Yin X; Zhang M; Yao J; He N; Armstrong CM; Zheng L; Zhang X; Zhu S; Sun X; Yang X; Zhao W; Liao B; Pan X; Nie L; Yang L; Chen Y; Zhao J; Zhang H; Dai J; Shen Y; Liu J; Huang R; Liu J; Wang Z; Ni Y; Wei Q; Li X; Zhou Q; Huang H; Liu Z; Shen P; Chen N; Zeng H
Nat Commun; 2021 Sep; 12(1):5262. PubMed ID: 34489456
[TBL] [Abstract][Full Text] [Related]
15. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
[TBL] [Abstract][Full Text] [Related]
16. Integrative clinical and molecular characterization of translocation renal cell carcinoma.
Bakouny Z; Sadagopan A; Ravi P; Metaferia NY; Li J; AbuHammad S; Tang S; Denize T; Garner ER; Gao X; Braun DA; Hirsch L; Steinharter JA; Bouchard G; Walton E; West D; Labaki C; Dudani S; Gan CL; Sethunath V; Carvalho FLF; Imamovic A; Ricker C; Vokes NI; Nyman J; Berchuck JE; Park J; Hirsch MS; Haq R; Mary Lee GS; McGregor BA; Chang SL; Feldman AS; Wu CJ; McDermott DF; Heng DYC; Signoretti S; Van Allen EM; Choueiri TK; Viswanathan SR
Cell Rep; 2022 Jan; 38(1):110190. PubMed ID: 34986355
[TBL] [Abstract][Full Text] [Related]
17. Melanotic MiT family translocation neoplasms: Expanding the clinical and molecular spectrum of this unique entity of tumors.
Saleeb RM; Srigley JR; Sweet J; Doucet C; Royal V; Chen YB; Brimo F; Evans A
Pathol Res Pract; 2017 Nov; 213(11):1412-1418. PubMed ID: 28969862
[TBL] [Abstract][Full Text] [Related]
18. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W
BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986
[TBL] [Abstract][Full Text] [Related]
19. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
20. TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.
Xu Y; Rao Q; Xia Q; Shi S; Shi Q; Ma H; Lu Z; Chen H; Zhou X
Int J Clin Exp Pathol; 2015; 8(3):2690-9. PubMed ID: 26045774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
